BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 12080466)

  • 1. The tumor suppressor activity of SOCS-1.
    Rottapel R; Ilangumaran S; Neale C; La Rose J; Ho JM; Nguyen MH; Barber D; Dubreuil P; de Sepulveda P
    Oncogene; 2002 Jun; 21(28):4351-62. PubMed ID: 12080466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation.
    Frantsve J; Schwaller J; Sternberg DW; Kutok J; Gilliland DG
    Mol Cell Biol; 2001 May; 21(10):3547-57. PubMed ID: 11313480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.
    Iwamoto T; Senga T; Naito Y; Matsuda S; Miyake Y; Yoshimura A; Hamaguchi M
    Oncogene; 2000 Sep; 19(41):4795-801. PubMed ID: 11032030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. v-Abl signaling disrupts SOCS-1 function in transformed pre-B cells.
    Limnander A; Danial NN; Rothman PB
    Mol Cell; 2004 Aug; 15(3):329-41. PubMed ID: 15304214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells.
    Monni R; Santos SC; Mauchauffe M; Berger R; Ghysdael J; Gouilleux F; Gisselbrecht S; Bernard O; Penard-Lacronique V
    Oncogene; 2001 Feb; 20(7):849-58. PubMed ID: 11314018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signaling 1 function.
    Flowers LO; Johnson HM; Mujtaba MG; Ellis MR; Haider SM; Subramaniam PS
    J Immunol; 2004 Jun; 172(12):7510-8. PubMed ID: 15187130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2.
    Kamizono S; Hanada T; Yasukawa H; Minoguchi S; Kato R; Minoguchi M; Hattori K; Hatakeyama S; Yada M; Morita S; Kitamura T; Kato H; Nakayama Ki ; Yoshimura A
    J Biol Chem; 2001 Apr; 276(16):12530-8. PubMed ID: 11278610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of inhibition of growth hormone receptor signaling by suppressor of cytokine signaling proteins.
    Hansen JA; Lindberg K; Hilton DJ; Nielsen JH; Billestrup N
    Mol Endocrinol; 1999 Nov; 13(11):1832-43. PubMed ID: 10551777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction.
    Nicholson SE; Willson TA; Farley A; Starr R; Zhang JG; Baca M; Alexander WS; Metcalf D; Hilton DJ; Nicola NA
    EMBO J; 1999 Jan; 18(2):375-85. PubMed ID: 9889194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor.
    Bousquet C; Susini C; Melmed S
    J Clin Invest; 1999 Nov; 104(9):1277-85. PubMed ID: 10545526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOCS-1, -2, -3: selective targets and functions downstream of the prolactin receptor.
    Tomic S; Chughtai N; Ali S
    Mol Cell Endocrinol; 1999 Dec; 158(1-2):45-54. PubMed ID: 10630404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
    Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
    Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.
    Ling X; Ma G; Sun T; Liu J; Arlinghaus RB
    Cancer Res; 2003 Jan; 63(2):298-303. PubMed ID: 12543778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine-inducible SH2-containing protein suppresses PRL signaling by binding the PRL receptor.
    Dif F; Saunier E; Demeneix B; Kelly PA; Edery M
    Endocrinology; 2001 Dec; 142(12):5286-93. PubMed ID: 11713228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A family of cytokine-inducible inhibitors of signalling.
    Starr R; Willson TA; Viney EM; Murray LJ; Rayner JR; Jenkins BJ; Gonda TJ; Alexander WS; Metcalf D; Nicola NA; Hilton DJ
    Nature; 1997 Jun; 387(6636):917-21. PubMed ID: 9202125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis.
    Qiu X; Guo G; Chen K; Kashiwada M; Druker BJ; Rothman PB; Chen JL
    Neoplasia; 2012 Jun; 14(6):547-58. PubMed ID: 22787435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling.
    Pezet A; Favre H; Kelly PA; Edery M
    J Biol Chem; 1999 Aug; 274(35):24497-502. PubMed ID: 10455112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of tyrosine 441 of interferon-gamma receptor subunit 1 in SOCS-1-mediated attenuation of STAT1 activation.
    Qing Y; Costa-Pereira AP; Watling D; Stark GR
    J Biol Chem; 2005 Jan; 280(3):1849-53. PubMed ID: 15522878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOCS-3 is involved in the downregulation of the acute insulin-like effects of growth hormone in rat adipocytes by inhibition of Jak2/IRS-1 signaling.
    Ridderstråle M; Amstrup J; Hilton DJ; Billestrup N; Tornqvist H
    Horm Metab Res; 2003 Mar; 35(3):169-77. PubMed ID: 12734778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK-STAT signaling activated by Abl oncogenes.
    Danial NN; Rothman P
    Oncogene; 2000 May; 19(21):2523-31. PubMed ID: 10851051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.